Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?

Autor: Walter P. Maksymowych, Robert D. Inman, Louis Bessette, Proton Rahman, Emmanouil Rampakakis, Odalis Asin-Milan, Meagan Rachich, Anne Marilise Marrache, Allen J. Lehman
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-9 (2023)
Druh dokumentu: article
ISSN: 1478-6362
DOI: 10.1186/s13075-023-03055-1
Popis: Abstract Objectives To (i) determine whether sustained disease activity states, as measured by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS), impact function, and (ii) evaluate characteristics predicting sustained low functional impairment in a prospective axial spondyloarthritis (axSpA) cohort. Methods Biologic Treatment Registry Across Canada (BioTRAC) was a multi-center, prospective registry that collected real-world data on axSpA patients receiving infliximab or golimumab between 2006 and 2017. Generalized estimating equations (GEE) were used to test baseline characteristics, treatment, and duration (at 6 and 12 months vs. only at 6 or 12 months vs. neither) of low BASDAI (
Databáze: Directory of Open Access Journals
Externí odkaz: